Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.

被引：4
|
作者：
Rahman, Rifaquat
Fell, Geoffrey
Trippa, Lorenzo
Alexander, Brian Michael
机构：
[1] Harvard Radiat Oncol Program, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Biostatist & Computat Biol, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA USA
[4] Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2543
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Professional medical writing assistance in oncology clinical trials.
    Jaoude, Joseph Abi
    Kouzy, Ramez
    Mainwaring, Walker
    Lin, Timothy
    Miller, Austin B.
    Jethanandani, Amit
    Espinoza, Andres F.
    Taniguchi, Cullen M.
    Ludmir, Ethan B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Trends in the design and interpretation of metastatic colorectal cancer phase III clinical trials.
    Parimi, Sunil
    Raissouni, Soundouss
    Lin, Yongtao
    Monzon, Jose Gerard
    Tang, Patricia A.
    Tam, Vincent Channing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [33] The hazards of randomized phase II trials
    Lara, P. N.
    Redman, M. W.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (03) : 810 - 812
  • [34] Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?
    Lowenstein, Pedro R.
    Castro, Maria G.
    [J]. CURRENT GENE THERAPY, 2009, 9 (05) : 368 - 374
  • [35] Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.
    Salawu, Abdulazeez
    Chen, Rachel
    Hernando-Calvo, Alberto
    Araujo, Daniel Vilarim
    Bernal, Marc Oliva
    Liu, Zhihui
    Siu, Lillian L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Use of Schoenfeld's global test to test the proportional hazards assumption in the Cox proportional hazards model: an application to a clinical study
    Abeysekera, W. W. M.
    Sooriyarachchi, M. R.
    [J]. JOURNAL OF THE NATIONAL SCIENCE FOUNDATION OF SRI LANKA, 2009, 37 (01): : 41 - 51
  • [37] Unexpected results from randomized clinical trials. Or are they?
    Donnez, Jacques
    [J]. FERTILITY AND STERILITY, 2019, 112 (05) : 804 - 805
  • [38] USING VERIFIED CLINICAL TRIALS' DATABASE REGISTRY TO DETERMINE THE PREVALENCE OF AND PREVENT EXCLUSION/INCLUSION RELATED PROTOCOL VIOLATIONS IN EARLY PHASE CLINICAL TRIALS.
    Zhang, Y.
    Wang, Y.
    DiBartolo-Cordovano, R.
    Weingard, K. K.
    Efros, M. D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S117 - S117
  • [39] CLINICAL RESEARCH IMPLEMENTATION COMMITTEE: AN INTEGRATED APPROACH TO ONCOLOGY CLINICAL TRIALS.
    Knoop, Teresa
    Richard, Vicki
    Atwell, Leah
    Gaynes, Lisa
    Hackett, Lauren
    [J]. ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [40] Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
    Castanon, Eduardo
    Sanchez-Arraez, Alvaro
    Alvarez-Mancenido, Felipe
    Jimenez-Fonseca, Paula
    Carmona-Bayonas, Alberto
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 136 : 159 - 168
12345